In hepatocytes, cAMP/PKA activity stimulates the exocytic insertion of apical proteins and lipids and the biogenesis of bile canalicular plasma membranes. Here, we show that the displacement of PKA-RII␣ from the Golgi apparatus severely delays the trafficking of the bile canalicular protein MDR1 (P-glycoprotein), but not that of MRP2 (cMOAT), DPP IV and 5NT, to newly formed apical surfaces. In addition, the direct trafficking of de novo synthesized glycosphingolipid analogues from the Golgi apparatus to the apical surface is inhibited. Instead, newly synthesized glucosylceramide analogues are rerouted to the basolateral surface via a vesicular pathway, from where they are subsequently endocytosed and delivered to the apical surface via transcytosis. Treatment of HepG2 cells with the glucosylceramide synthase inhibitor PDMP delays the appearance of MDR1, but not MRP2, DPP IV, and 5NT at newly formed apical surfaces, implicating glucosylceramide synthesis as an important parameter for the efficient Golgi-to-apical surface transport of MDR1. Neither PKA-RII␣ displacement nor PDMP inhibited (cAMP-stimulated) apical plasma membrane biogenesis per se, suggesting that other cAMP effectors may play a role in canalicular development. Taken together, our data implicate the involvement of PKA-RII␣ anchoring in the efficient direct apical targeting of distinct proteins and glycosphingolipids to newly formed apical plasma membrane domains and suggest that rerouting of Golgi-derived glycosphingolipids may underlie the delayed Golgi-to-apical surface transport of MDR1.
INTRODUCTION
The apical surface of epithelial cells is a functionally and structurally specialized membrane domain that faces the body exterior. In hepatocytes, the predominant epithelial cells of the liver, the apical surface delineates the bile canalicular space and is formed by local remodeling of the cell surface after the initiation of cell-cell adhesion. Local retention in conjunction with the intracellular sorting and targeting of newly synthesized and recycling canalicular and sinusoidal proteins and lipids is crucial in generating and maintaining cell surface polarity. Hepatocytes typically employ two pathways by which proteins and lipids are transported to the apical surface, a direct pathway and an indirect route that involves initial delivery to the basolateral surface followed by transcytosis to the apical domain.
Many studies have implicated the second-messenger cAMP in apical membrane dynamics in various epithelial cells (Hansen et al., 1995; Brignoni et al., 1995; Knepper and Inoue, 1997; Valenti et al., 1998; Ward et al., 1999; Howard et al., 2000; Butterworth et al., 2001 Butterworth et al., , 2005 Jo et al., 2001; Truschel et al., 2002; Karvar et al., 2002; Yao and Forte, 2003; Tietz et al., 2003; Thomas et al., 2004; Burgos et al., 2004; Wang et al., 2005) , including hepatocytes (van IJzendoorn et al., 1997 (van IJzendoorn et al., , 1998 (van IJzendoorn et al., , 1999 (van IJzendoorn et al., , 2000 Zegers and Hoekstra, 1997; Roelofsen et al., 1998; Kipp and Arias, 2001; Kagawa et al., 2002; Gradilone et al., 2003) . These studies generally concluded that increased cellular levels of cAMP promote apical surface-directed trafficking of exocytic transport vesicles that carry apical proteins and lipids and has lead to suggest that cAMP controls the abundance of canalicular proteins in order to meet changing physiological demands (Snyder, 2000; Garcia et al., 2001; Kipp et al., 2001; Gradilone et al., 2003; Wang et al., 2005) . Furthermore, the cAMP-regulated recruitment of apical proteins and lipids from the Golgi and subapical recycling endosomes appears to be tightly linked to the formation of apical canalicular domains in hepatocytes (Zegers and Hoekstra, 1997; van IJzendoorn and Hoekstra, 2000) .
Despite the clear evidence implicating cAMP levels in apical membrane dynamics, surprisingly little is known about the molecular players that act upstream and downstream of cAMP in controlling apical surface dynamics. In hepatocytes, elevated cellular levels of cAMP stimulate the activity of dihydroceramide synthase, an enzyme early in the sphingolipid metabolic pathway that is responsible for converting sphinganine to ceramides. Inhibition of dihydroceramide synthase and subsequent accumulation of sphinganine frustrates cAMP-stimulated recycling endosome dynamics and results in impaired bile canalicular plasma membrane biogenesis (van IJzendoorn et al., 2004) . The cAMP-mediated activation of PKA stimulates apical surface-directed trafficking of lipids and apical plasma membrane development in hepatocytes, and this is blocked by the inhibition of the catalytic activity of PKA (Zegers and Hoekstra, 1997; van IJzendoorn and Hoekstra, 2000) . Simi- larly, the inhibition of PKA activity blocks forskolin-stimulated translocation of water channels to the apical surface in renal collecting duct principal cells (Klussmann et al., 1999) . Very few PKA substrates that act in apical membrane dynamics have been reported. In parietal cells, the PKA-mediated phosphorylation of ezrin appears to play an important role in mediating the remodeling of the apical membrane cytoskeleton associated with cAMP-stimulated acid secretion (Zhou et al., 2003) .
In mammalian cells, PKA exists as two isoforms, type I and type II, which are distinguished by their different regulatory subunits, RI and RII. One regulatory subunit dimer is bound by two catalytic subunits, forming a tetrameric structure. Binding of two cAMP molecules to each regulatory subunit relieves the PKA autoinhibitory contact, which allows dissociation of the catalytic subunits, and results in phosphorylation of local substrates. PKA type I is primarily cytoplasmic and displays a higher sensitivity to cAMP when compared with PKA type II. By contrast, most PKA type II is anchored at specific organelles and cellular structures via binding to A-kinase anchoring proteins (AKAPs), which provides an important level of control to ensure specificity of cAMP-mediated signal transduction. Differences in cAMP affinity and subcellular localization between the two PKA types are proposed to contribute to specificity in physiological responses (Michel and Scott, 2002) .
We have previously observed that the process of cAMP/ PKA-stimulated endosomal membrane recruitment and coinciding bile canalicular plasma membrane biogenesis is regulated by signaling cascades elicited by oncostatin M, an IL-6 family cytokine that plays an important role in fetal liver development (Miyajima et al., 2000; Kinoshita and Miyajima, 2002) . Oncostatin M-stimulated apical trafficking and bile canalicular plasma membrane biogenesis was blocked by inhibitors of catalytic PKA activity (van der Wouden et al., 2002) . Intriguingly, whereas we did not observe changes in cellular cAMP levels in response to oncostatin M, the cytokine stimulated the association of PKA-RII␣ with the centrosome/Golgi region of hepatocytes (van der Wouden et al., 2002) , suggesting that local PKA-RII␣ anchoring may play a role in apical membrane dynamics. In this study, we have investigated the involvement of PKA-RII␣ anchoring in trafficking of canalicular proteins and lipids and apical bile canalicular plasma membrane biogenesis. We find that PKA-RII␣ anchoring is dispensable for apical surface biogenesis per se but is required for the efficient and coordinated apical delivery of a subset of proteins and sphingolipids.
MATERIALS AND METHODS

Cell Culture
HepG2 cells were cultured in high glucose (4500 mg/l) DMEM, supplemented with 10% heat-inactivated fetal calf serum (56°C; 30 min), l-glutamine, and antibiotics (penicillin/streptomycin) at 37°C in a 5% CO 2 -humidified incubator, as described previously (van IJzendoorn and Hoekstra, 1998) . For experiments, cells were plated onto ethanol-sterilized glass coverslips and cultured for 1-3 d. In some experiments, cells were plated in the presence of 10 M PDMP.
Transfection and Generation of Stable Cell Lines
HepG2 cells were transfected with the YFP-and V 5 epitope-tagged AKAP-IS construct provided by J. Scott (described in detail elsewhere; Alto et al., 2003) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol. After 4 h, G418 (0.8 mg/ml) was included in order to select transfected cells. Several clones were isolated and screened for the expression of V 5 epitope and YFP, using monoclonal anti-V 5 (Invitrogen) and anti-YFP (Roche, Indianapolis, IN) antibodies, respectively, in combination with corresponding AP-conjugated secondary antibodies (Chemicon International, Temecula, CA) for Western blotting and Alexa Fluor-conjugated secondary antibodies (Molecular Probes, Eugene, OR) for immunofluorescence microscopy. Experiments were performed in two different clones of HepG2 cells expressing comparable expression levels of the peptide (HepG2/IS-5 and HepG2/IS-1 cells), and both clones showed comparable results. Only data obtained in HepG2/IS-5 cells are shown.
Immunoprecipitations
For coimmunoprecipitation of PKA RII␣ associated with Golgi AKAP's, HepG2 and HepG2/IS-5 cells were harvested in lysis buffer containing NP-40, pH 7.4, supplemented with protease inhibitors (1 g/ml aprotinin, 100 M benzamidin, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin A). Lysates of HepG2 and HepG2/IS-5 cells were incubated overnight at 4°C with rabbit polyclonal anti-BIG2 antibodies on a rocker, followed by addition of a 50% protein A Sepharose beads slurry (Amersham). Antibody-antigen complexes were precipitated by centrifugation at 12000 ϫ g for 30 s and washed three times with ice-cold lysis buffer.
Subcellular Fractionation
Cells were grown to 80% confluency, washed, and scraped in ice-cold fractionation buffer (140 mM KCl, 20 mM HEPES pH 7.4, 1 g/ml aprotinin, 100 M benzamidin, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin A) and homogenized with a Dounce homogenizer. Nuclei were pelleted at 10000 ϫ g at 4°C for 10 min, and the supernatant consisting of cytosol and membranes was transferred to ultracentrifuge tubes (Beckman 344057) and separated by centrifugation at 100,000 ϫ g, at 4°C for 30 min. The pellet (membrane fraction) was resuspended in ice-cold fractionation buffer.
SDS-PAGE and Western Blotting
For immunoprecipitation experiments, beads containing antibody-antigen complexes were resuspended in sample buffer (2% SDS, 1% ␤-mercaptoethanol, 10% glycerol, 50 mM Tris, pH 6.8, 0.02% BFB) and boiled for 4 min. Samples were then spun down and supernatants were applied onto SDS-PAGE (8% acrylamide) followed by transfer onto nitrocellulose membranes. For the subcellular fractionation experiments, proteins (10 g) from isolated cytosolic and membrane fractions were first TCA-precipitated, and the resulting pellets were resuspended in sample buffer, boiled for 4 min, separated with SDS-PAGE and transferred to PVDF blot membranes. Membranes were blocked with 1% milk in phosphate-buffered saline-Tween 20 (0.3%; PBST) and incubated with antibodies against PKA-RII␣, V 5 , or BIG2 at room temperature for 2 h. Membranes were then washed three times for 5 min with PBST and incubated with corresponding secondary HRP-conjugated antibodies (Amersham, Piscataway, NJ) at room temperature for 1 h and processed for enhanced chemiluminescence (ECL) detection (Amersham). Bands were quantified using free Scion Imaging software (Frederick, MD).
Antibody Staining
Cells were fixed with 4% paraformaldehyde (PFA) at 4°C for 30 min, washed, and permeabilized with 0.1% Triton X-100 at 37°for 10 min. Cells were subsequently incubated with primary monoclonal antibodies against giantin, BIG2, MDR1 (C219), MRP2 (M2-III6; Alexis Biochemicals, San Diego, CA), 5ЈNT, or DPP IV (Aït Slimane et al., 2003) . Cells were then washed and incubated with the corresponding secondary antibody labeled with Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probes) and the nuclear stain DAPI. The coverslips were mounted and analyzed by fluorescence microscopy (Provis AX70; Olympus, New Hyde Park, NY).
Determination of HepG2 Cell Polarity
Accurate estimation of the degree of HepG2 polarity was performed as described elsewhere (van IJzendoorn and Hoekstra, 2000) . Cells were fixed with Ϫ20°C ethanol for 10 s and rehydrated in Hanks' balanced salt solution (HBSS). Cells were then incubated with a mixture of TRITC-labeled phalloidin and the nuclear stain Hoechst 33528 at room temperature for 20 min. The cells were then washed, and the number of BC (identified by the presence of dense F-actin staining around BC) per 100 cells (identified by fluorescently labeled nuclei) was determined and expressed as the ratio [BC/100 cells]. Ten fields (each containing Ͼ50 cells) per coverslip (at least 2 coverslips per condition were studied) were analyzed.
Quantification of Apical Lumens Containing Apical Proteins
The presence of apical proteins at bile canalicular structures was determined semiquantitatively by assessing the percentage of fluorescently labeled bile canaliculi following the antibody staining protocol (see above). The bile canaliculi, which are first visualized under phase-contrast by their microvillar appearance, were subsequently classified as fluorescently labeled or not under epifluorescence illumination. Data are expressed as mean Ϯ SD of three independent experiments carried out in duplicate. At least 500 cells were analyzed per sample.
Cell Labeling and Lipid Transport Assays
Insertion and Back Exchange of Fluorescent Lipids. Treated or untreated cells were washed three times with cold HBSS. C 6 -NBD-lipids were added to cold HBSS by means of ethanolic injection. Lipids from a stock solution in chloroform/methanol (2:1 vol/vol) were dried under nitrogen and solubilized in absolute ethanol. The ethanolic solution was subsequently injected into HBSS under vigorous vortexing. The final concentration of ethanol did not exceed 0.5% (vol/vol).
When required, C 6 -NBD-lipids present in the outer leaflet of the plasma membrane were removed by a back exchange procedure. To this end the cells were incubated for 30 min at 4°C with 5% BSA in HBSS, followed by washing with cold HBSS. This procedure was repeated once.
Apical Delivery of De Novo Synthesized Lipids.
Treated or untreated cells were plated on coverslips and labeled with C 6 -NBD-Cer for 60 min at room temperature. To allow for synthesis of C 6 -NBD-glucosylceramide (GlcCer) or -sphingomyelin (SM) and their subsequent transport, an incubation was carried out at 37°C for 60 min in HBSS with or without 5% BSA. Cells that were incubated at 37°C in the absence of back-exchange medium (HBSS containing 5% BSA) were subjected to a back exchange afterward. The apical labeling of the bile canalicular structures was determined semiquantitatively by assessing the percentage of bile canaliculi that was NBD positive. The bile canaliculi, which are easily visualized under phase-contrast by their microvillar appearance, were classified as NBD positive or negative under epifluorescence illumination. In control cells, 50 -70% of the total population of bile canaliculi was NBD positive after a 60-min incubation period at 37°C. Cells that were incubated with NBD-lipids at 4°C only showed a background labeling of bile canaliculi of ϳ10% of the total population (cf. Zegers and Hoekstra, 1998) .
Metabolism of C 6 -NBD-Cer and Basolateral Delivery of De
Novo-synthesized Sphingolipids. Cells were labeled with C 6 -NBD-Cer for 60 min at room temperature. The cells were then incubated for 60 min at 37°C in HBSS containing 5% BSA. Subsequently they were washed and scraped from the culture dish. Lipids from the incubation medium and cells were extracted and quantified as described below.
Lipid Extraction and Quantification. Lipids from cells and back-exchange media were extracted according to the method of Bligh and Dyer. The lipids were separated and analyzed by TLC, using CHCI 3 /methanol/NH 4 OH/H 2 O (35:15:2:0.5, vol/vol/vol/vol) as a running solvent. Lipid amounts were quantified by scraping the spots from the TLC plates, followed by vigorous shaking in 1% (vol/vol) TX-100 in H 2 O for 60 min. After removal of silica particles by centrifugation, NBD-fluorescence was measured as described above.
Basolateral-to-Apical Transcytosis of C 6 -NBD-SM and C 6 -NBD-GlcCer. C 6 -NBD-SM or -GlcCer was incorporated in the basolateral plasma membrane at 4°C for 30 min. Cells were then washed, and transcytosis to the apical domain was allowed by incubating the cells at 37°C for 30 min in HBSS. After a subsequent BSA back-exchange procedure at 4°C, cells were processed for fluorescent microscopic analyses. The apical labeling of the bile canalicular structures was determined semiquantitatively by assessing the percentage of bile canaliculi that was NBD positive. The bile canaliculi, which are easily visualized under phase-contrast by their microvillar appearance, were classified as NBD positive or negative under epifluorescence illumination.
RESULTS
Expression of the AKAP-IS Peptide in HepG2 Cells
Displaces PKA-RII␣ from Golgi-associated PKA Anchoring Proteins To examine the involvement of PKA and its subcellular anchoring in Golgi-to-apical, bile canalicular plasma membrane (BC) trafficking of canalicular proteins via either the direct or indirect (transcytotic) pathway, we constructed well-differentiated hepatoma HepG2 cells that stably express an RII-specific peptide (V 5 -AKAP-IS) that binds to the PKA type II holoenzyme and displaces it from its natural anchoring sites (Alto et al., 2003) . Indeed, Figure 1A shows that, although a significant fraction of PKA-RII␣ is associated with membranes in HepG2 cells (the ratio of membrane-associated PKA-RII␣ over cytosolic PKA-RII␣ is 1.89; Figure 1B ), PKA-RII␣ is effectively displaced from cellular membranes to the cytosol in HepG2 cells expressing the AKAP-IS peptide (HepG2/IS-5 cells; the ratio of membraneassociated PKA-RII␣ over cytosolic PKA-RII␣ is 0.42; Figure  1B) , consistent with the exclusive localization of the V 5 -tagged AKAP-IS peptide in the cytosol ( Figure 1A) . The anti-PKA-RII␣ antibodies available to us were not suitable for studying the intracellular localization of PKA-RII␣ in HepG2 cells by means of immunofluorescence microscopy. However, PKA-RII␣ clearly coimmunoprecipitates with at least two AKAPs, AKAP350 (unpublished data) and BIG2 ( Figure 1D ), which predominantly localizes to the Golgi apparatus (marked by the presence of giantin; Figure 1C ), consistent with previous observations (Li et al., 2003) . Importantly, coimmunoprecipitation experiments show that expression of the AKAP-IS peptide results in a pronounced decrease (ϳ90%) of the interaction between PKA-RII␣ and BIG2 ( Figure 1D ) and, to a lesser extent between PKA-RII␣ and AKAP350 (ϳ60% reduction; unpublished data), whereas total BIG2 and PKA-RII␣ expression levels remained constant (Figure 1, E and F, respectively) . Together, these data demonstrate that the stable expression of the AKAP-IS peptide in HepG2 cells inhibits the anchoring of PKA-RII␣ to Golgi-associated AKAPs.
PKA-RII␣ Displacement Delays Trafficking of Specific Proteins to Newly Formed Apical Plasma Membranes
Parental HepG2 and HepG2/IS-5 cells were cultured onto glass coverslips for different time intervals to allow for the de novo formation of apical plasma membrane domains, i.e., cell polarity development (Zegers and Hoekstra, 1997) . At 24, 48, and 72 h after plating, the cells were fixed with 4% PFA and processed for indirect immunofluorescent detection of various apical canalicular proteins, including the multi-membrane-spanning ABC transporters MDR1/p-glycoprotein (Aït Slimane et al., 2003) and MRP2/cMOAT (Cantz et al., 2000; Kubitz et al., 2001) , the single-membranespanning protein dipeptidyl peptidase (DPP) IV (Bartles et al., 1991; Aït Slimane et al., 2003) , and the glycosylphosphatidylinostitol (GPI)-anchored 5Ј nucleotidase (NT; Schell et al., 1992; Tuma et al., 1999) . Apical plasma membrane domains (BC) are first identified under phase-contrast and subse- quently analyzed for the presence of absence of the apical proteins with epifluorescence. This dual analysis allows us to study in parallel the de novo formation of apical plasma membrane domains and the presence of apical proteins at these domains.
At 24 h after plating of the parental HepG2 cells, most apical plasma membranes identified with phase-contrast microscopy stained positive for MDR1 (Figure 2 (Figure 4 ). Of these, 24 (95%) and 31 (Ͼ95%), respectively, harbored all apical proteins examined (Figure 2 , D-I; 3, D-F, J-L, and P-R; and 4, A, C, E, and G). These data suggest that the different apical proteins are readily sorted to the newly formed apical surfaces. However, a closer examination of the trafficking of these various proteins revealed that the kinetics by which MDR1 and DPP IV appear in BC differ from that of MRP2 and 5Ј NT.
In contrast to parental HepG2 cells, HepG2/IS-5 cells displayed a striking delay in the trafficking of MDR1 to the apical surfaces. Indeed, 24 h after plating, most apical lumens were devoid of MDR1, which instead predominantly localized to small uniform punctate structures distributed throughout the cytoplasm (Figure 2 , J-L, apical lumens are marked with an asterisk). MDR1 did not accumulate in a location that could be visualized with immunofluorescence microscopy, and no colocalization of MDR1 was observed with markers of the Golgi apparatus or endosomes (unpublished data). Moreover, a lack of fluorescent signal after immunostaining of nonpermeabilized 24-h-old cells with a monoclonal antibody (4E3) that recognizes an extracellular epitope of MDR1 (Aït Slimane et al., 2003) suggest that MDR1 was not transported to the basolateral surface, but was rather retained intracellularly (Supplementary Figure  S1) . Importantly, the displacement of PKA-RII␣ did not affect the total expression level of MDR1, which was similar to that in parental HepG2 cells (Supplementary Figure S2A) . After another 24 h of culture, MDR1 subsequently displayed a gradual apical plasma membrane appearance (Figure 2 , M-O, apical lumens are marked with an asterisk) and reached an exclusive apical localization at 72 h (Figure 2 , P-R). Quantitative microscopic analyses ( Figure 4B ) confirmed that in HepG2/IS-5 cells, Ͻ25% of the apical lumens, identified by phase contrast, contained MDR1 after 24 h (compare with 67% in control cells), which increased to ϳ50% at 48 h (compare with 95% in control cells). These data suggest that the displacement of PKA-RII␣ severely delays the direct trafficking of MDR1 to apical plasma membrane domains.
Interestingly, the trafficking of other resident apical proteins to apical surfaces appeared unaffected in HepG2/IS-5 cells. Thus, MRP2, DPP IV, and 5ЈNT localized exclusively at the apical surface at all times, and the kinetics of their appearance at newly formed apical membranes was indistinguishable from that observed in control cells (Figures 3,  D-F , J-L, P-R, and 4, B, D, F, and H). Therefore, the effect of PKA-RII␣ displacement on the trafficking of the different apical proteins tested appears to be specific for MDR1. Note that apical plasma membrane biogenesis and subsequent development per se, indicated by an increasing ratio BC/100 cells, is not significantly affected in HepG2/IS-5 cells (Figure 4 , A, C, E, and G vs. 4, B, D, F, and H), suggesting that overall cell polarity development as such is not dependent on PKA-RII␣ anchoring.
PKA-RII␣ Displacement Delays the Delivery of MDR1 to Newly Formed Apical Domains in Response to Dibutyryl cAMP
Treatment of HepG2 cells with the stable cAMP analogue dibutyryl cAMP (dbcAMP) stimulates the biogenesis of apical plasma membrane domains in HepG2 cells in a PKAdependent manner. The cAMP/PKA-stimulated apical plasma membrane biogenesis was shown to coincide with an increased apical-directed flow of membranes originating from the Golgi apparatus (Zegers and Hoekstra, 1997 ) and the endosomal system Hoekstra, 1999, 2000) . To examine the involvement of PKA anchoring in this event, HepG2 or HepG2/IS-5 cells were cultured for 3 d, followed by an incubation in buffer (control) or buffer sup- HepG2 or HepG2/IS-5 cells were cultured for 3 d and incubated with 4 M C6-NBDCer at room temperature for 1 h, washed, and incubated at 37 or 4°C for another hour in HBSS. In some experiments, the multidrug resistance protein inhibitor MK571 (MK) was included in the incubation medium. After the incubation, the cells were scraped in ice-cold HBSS. Lipid were extracted and C6-NBDlabeled sphingolipid analogues were separated with TLC and quantified as described in Materials and Methods. Depicted in the table are the percentage of C6-NBD-Cer that was metabolized (total SPL product), and the fraction of that which is represented by C6-NBD-SM or -GC (total SM and total GC).
plemented with 100 M dbcAMP at 37°C for 1 h. Cells were then fixed and processed for polarity development analysis (see Materials and Methods). As reported in our previous studies, treatment of HepG2 cells with dbcAMP resulted in an increase in the ratio of apical domains per 100 cells with ϳ30% ( Figure 5A , control (nontreated cells) set to 100%; cf. Zegers and Hoekstra, 1997) . A very similar increase in apical plasma membrane biogenesis was observed in dbcAMPtreated HepG2/IS-5 cells ( Figure 5A ), suggesting that PKA-RII␣ anchoring is not essential for cAMP/PKA-mediated stimulation of apical plasma membrane biogenesis. However, although, in control cells, the dbcAMP-stimulated increase in the number of apical surfaces (i.e., BCs) was matched by an increase in the number of MDR1-positive apical surfaces (ratio MDR1-positive BC/total BC ϭ 1), the percentage of MDR1-positive apical domains in dbcAMPtreated HepG2/IS-5 cells was reduced to ϳ65% ( Figure 5B , control set to 100%), strongly suggesting that MDR1 trafficking failed to catch up with the development of new apical surface domains in these cells. Because the membrane organization of MDR1, and apical surface-directed trafficking in general, has previously been proposed to be related to (glyco)sphingolipid dynamics (Zegers et al., 1998; Sietsma et al., 2001) , we next investigated the dependency of the latter on PKA-RII␣ anchoring.
PKA-RII␣ Displacement Inhibits Golgi-to-Apical Surface Trafficking and Causes Missorting of Newly Synthesized Glycosphingolipid Analogues
First, we examined the effect of PKA-RII␣ displacement on the de novo synthesis and trafficking of newly synthesized sphingolipids. For this, we used fluorescently (C6-NBD) labeled ceramide (C6-NBD-Cer). Addition of C6-NBD-Cer to HepG2 cells results in the accumulation of the lipid analogue in the Golgi apparatus, followed by its conversion to C6-NBD-SM and -GlcCer (Zegers and Hoekstra, 1997; Zegers et al., 1998; Maier and Hoekstra, 2003) .
To study the trafficking of newly synthesized sphingolipids from the Golgi to the apical surface, HepG2 and HepG2/ IS-5 cells were first incubated with 4 M C6-NBD-Cer at room temperature for 60 min, washed, and again incubated at 37°C for another 60 min in HBSS. In one set of experiments, BSA (5%, wt/vol) was added to the second incubation medium, which captures any C6-NBD-lipid that arrives at the basolateral surface, thereby preventing reentry of the lipid analogues and subsequent apical delivery via transcytosis. BSA does not have access to the apical lumens (van IJzendoorn et al., 1997) and, therefore, allows for the study of direct Golgi-to-apical surface trafficking of C6-NBD-lipids (Zaal et al., 1994; Zegers and Hoekstra, 1997) . After the second incubation, cells were washed three times with icecold HBSS and the percentage of NBD-labeled apical plasma membrane domains was determined by fluorescence microscopy as described in MATERIALS AND METHODS. The de novo synthesis of C6-NBD-SM and -GlcCer from C6-NBD-Cer was not affected by PKA-RII␣ displacement (Table 1) . Indeed, in both control and HepG2/IS-5 cells, ϳ50% of the C6-NBD-Cer was converted to C6-NBD-SM and -GlcCer, in a ratio of 3-1, respectively, similarly as reported previously (Zegers and Hoekstra, 1997; Maier and Hoekstra, 2003) . As shown in Figure 6B , newly synthesized C6-NBD-sphingolipids (mostly C6-NBD-GlcCer; Maier and Hoekstra, 2003) readily reached the apical plasma membranes (marked by the asterisk in the corresponding phasecontrast image in Figure 6A ) via the direct pathway in HepG2 cells. By contrast, in HepG2/IS-5 cells, C6-NBDsphingolipids were hardly detected at the apical surface (marked with the asterisk in Figure 6 , I and J), whereas labeling of the Golgi apparatus was apparent (Figure 6J, arrows) . Quantitative analyses demonstrated that in control cells ϳ50% of the BC were positively labeled with NBDlipids, whereas in HepG2/IS-5 cells this percentage was reduced to ϳ8% ( Figure 7A ). Interestingly, when BSA was omitted from the second incubation medium, allowing lipid analogues to travel to the apical domain via the basolateral surface, BC (marked with the asterisk in the phase-contrast panels) were readily labeled with C6-NBD-lipid analogues in both control HepG2 (Figure 6 , C and D) and HepG2/IS-5 cells ( Figure 6 , K and L). Quantitative analyses showed that in the absence of BSA, ϳ70 and 55% of the BC were NBD positive in HepG2 and HepG2/IS-5 cells, respectively. These data suggest that PKA-RII␣ displacement inhibits direct Golgi-to-apical plasma membrane trafficking of newly synthesized sphingolipid analogues, but does not prevent their indirect apical surface targeting by transcytosis via the basolateral surface. Indeed, when the basolateral plasma membrane of HepG2 (Figure 6 , E-H) or HepG2/IS-5 (Figure 6 , M-P) cells was incubated in medium containing C 6 -NBD-SM (Figure 6 , E, F, M, and N) or -GlcCer (Figure 6 , G, H, O, and P), transcytosis of the lipid probes readily occurred as evidenced by the appearance of fluorescently la- (A) Cells were treated as described in Figure 6 . The apical labeling of the bile canalicular structures was then determined semiquantitatively by assessing the percentage of bile canaliculi that was NBD positive. The bile canaliculi, which are easily visualized under phase-contrast by their microvillar appearance, were classified as NBD positive or negative under epifluorescence illumination. In control cells, 50 -70% of the total population of bile canaliculi was NBD positive after a 60-min incubation period at 37°C. Note the reduced apical labeling in HepG2/IS-5 cells when chased in the presence of BSA. (B) Cells were incubated with 4 M C6-NBD-Cer at room temperature for 1 h, washed, and incubated at 37 or 4°C for another hour in the presence of BSA in the medium. In some experiments, the multidrug resistance protein inhibitor MK571 was included in the medium. After the incubation, the BSA fractions were collected and cells were scraped. Lipid was extracted from the BSA fractions and cells were subjected to TLC and quantification as described in Materials and Methods. White and hatched bars represent C6-NBD-sphingomyelin (S) and -GlcCer (G), respectively. beled transport vesicles and apical plasma membrane domains (marked by the asterisk in the corresponding phasecontrast panels).
Quantification of the percentage of newly synthesized C6-NBD-SM and -GlcCer that was delivered to the basolateral surface in HepG2 and HepG2/IS-5 cells revealed that in control HepG2 cells, ϳ65 and 50% of newly synthesized SM and GlcCer analogues were transported to the basolateral surface ( Figure 7B ). In HepG2/IS-5 cells, this percentage was significantly increased to 79 and Ͼ85%, respectively ( Figure  7B ). Basolateral delivery of the lipid analogues in HepG2/ IS-5 cells, but not their synthesis, was inhibited when the temperature was lowered to 4°C ( Figure 7B ; Table 1 ), suggesting that transport occurred by vesicular means. This was further supported by the observation that inhibition of potential basolaterally localized (NBD-)lipid translocators with MK571 did not prevent basolateral delivery of the lipid analogues ( Figure 7B ), indicating that these did not reach the basolateral surface via monomeric flow followed by membrane translocation (van Helvoort et al., 1996) . Taken together, we conclude that PKA-RII␣ displacement selectively excludes newly synthesized sphingolipid analogues from the direct Golgi-to-apical plasma membrane trafficking route and causes their rerouting to the basolateral surface via a vesicular route.
Given the rerouting of de novo-synthesized glycosphingolipid analogues from the direct route into the indirect pathway and the coinciding severe delay in MDR1 appearance at the apical surfaces in HepG2/IS-5 cells, we next used inhibitors of endogenous glycosphingolipids to examine the glycosphingolipid dependency of apical plasma membranedirected MDR1 trafficking. 
Inhibition of GlcCer Synthesis Inhibits Golgi-to-Apical Surface Trafficking of MDR1 and Causes Its Missorting to the Basolateral Area
To investigate the glycosphingolipid-dependence of the appearance of MDR1 at newly formed apical plasma membrane domains, we cultured control HepG2 cells in the absence (control) or presence of the glucosylceramide synthase inhibitor PDMP (10 M). After 24, 48, and 72 h of culture, cells were fixed with 4% paraformaldehyde and processed for indirect immunofluorescent analyses of MDR1 and other resident apical proteins, as described in Materials and Methods. Treatment of HepG2 cells with PDMP resulted in a delay in the appearance of MDR1 at the newly formed apical surface (Figure 8 , A-C, BC is marked with an asterisk in B and C; compare to Figure 2 , A-C) during the first 24 h of culturing, very similar to that observed in HepG2/IS-5 cells (cf. Figure 2 , J-L). Indeed, whereas in control cells, MDR1 occupied ϳ75% of apical plasma membrane domains identified with phase-contrast microscopy, this percentage was significantly reduced to ϳ20% in PDMP-treated cells ( Figure 9A ). For comparison, in HepG2/IS-5 cells, this percentage was ϳ25% ( Figure 4B ). After 48 h of culture in the presence of PDMP, some apical plasma membrane domains displayed MDR1 (Figure 8 , D-F, arrow), whereas other BC did not contain MDR1 (Figure 8, asterisk) . Quantitative analyses showed that after 48 h of culture in the presence of PDMP, ϳ50% of the apical plasma membrane domains contained MDR1 (Figure 9B ), similar to that observed in HepG2/IS-5 cells (cf. Figure 4B ), but in striking contrast to the 75% MDR1-positive apical domains in control HepG2 cells ( Figure 9B ). Different from that observed in either control HepG2 or HepG2/IS-5 cells, MDR1 seemed to appear at the basolateral area of the PDMP-treated cells (Figure 8 , G-I). We were not able to determine unambiguously whether MDR1 in PDMP-treated cells localized at the basolateral cell surface or in small vesicles underneath the surface. Regardless, the absence of MDR1 from the apical surface is clear. The inhibition of GlcCer synthesis did not visibly affect the apical appearance of another apical ABC transporter protein, MRP2 (Figure 8 , J-R, and Figure 9 ) or 5ЈNT or DPP IV (our unpublished results). Finally, incubating the cells with short chain C2-and C6-ceramides did not affect MDR1 trafficking to the apical domains (unpublished data; cf. Figures 2, A-I, and 3A) , suggesting that the observed effect of PDMP is not due to an accumulation of ceramide. Together, these data suggest that the inhibition of glucosylceramide synthase causes an initial delay in the appearance of MDR1, but not other apical proteins, at newly formed apical surfaces.
DISCUSSION
In the present work we have obtained novel insight in the regulation of exocytic insertion of different apical bile canalicular proteins and (glyco)sphingolipids into newly formed bile canalicular membranes. Hepatocytes employ at least two distinct routes for the targeting of proteins and lipids to the canalicular membrane, a direct route from the Golgi apparatus to the apical domain, and an indirect route that involves prior delivery to the basolateral surface, followed by apical targeting via transcytosis. Most single-membranespanning and GPI-anchored ectoenzymes such as DPP IV and 5ЈNT, respectively, follow the indirect pathway (Schell et al., 1992; Aït Slimane et al., 2003) . Multi-membrane-spanning ABC transporters such as MDR1 and MRP2 are targeted to the apical domain without passing the basolateral surface (Kipp and Arias, 2000; Aït Slimane et al., 2003) . Both pathways are used by de novo synthesized (glyco)sphingolipids (Zaal et al., 1994; Zegers and Hoekstra, 1997; Zegers et al., 1998) .
cAMP regulates the exocytic insertion of apical proteins and lipids and, in this way, their abundance at the canalicular membrane. Studies using isolated hepatocyte couplets, hepatocyte cell lines, or perfused rat livers have suggested that cAMP stimulates the exocytic trafficking of Golgi-, basolateral plasma membrane-, and recycling endosome-derived vesicles containing canalicular proteins and lipids (see Introduction). Binding of cAMP to the regulatory subunits of PKA heterodimers induces their dissociation from the catalytic subunits and results in PKA activation. An important level of control to ensure specificity of cAMP-mediated signal transduction is achieved by directing and anchoring PKA to subcellular sites through association of the regulatory subunits with AKAPs (reviewed in Colledge and Scott, 1999; Edwards and Scott, 2000) . In HepG2/IS-5 cells that stably express an RII-specific peptide that binds to the PKA holoenzyme and displaces it from the PKA-anchoring protein BIG2 at the Golgi apparatus, a significant delay in the appearance of MDR1, but not of MRP2, at the canalicular domains was observed. Only after 48 h of culture, ϳ50% of the apical surfaces contained modest amounts of MDR1, which increased to normal levels after 72 h of culture. At no time did we observe MDR1 at the basolateral domain, suggesting that PKA-RII␣ displacement does not cause MDR1 missorting. In HepG2/IS-5 cells, MRP2, DPP IV, and 5ЈNT appeared at the newly formed apical surfaces with unaltered kinetics, suggesting that basolateral to apical transcytosis does not require PKA-RII␣ anchoring. Therefore, the anchoring of PKA-RII␣ appears to be specifically involved in the efficient trafficking of a subset of canalicular proteins, in this case MDR1, that travel along a direct pathway to the canalicular domain. It is possible that PKA-RII displacement affects a specific trafficking route that may be followed by other yet unidentified canalicular proteins in addition to MDR1.
The inhibition of PKA-RII␣ anchoring does not significantly affect the de novo biogenesis of canalicular plasma membrane domains. Interestingly, however, apical plasma membrane biogenesis in HepG2 cells has previously been shown to depend on endogenous PKA activation. Indeed, inhibition of the catalytic activity of PKA abrogated basolateral-apical polarity development (van IJzendoorn and Hoekstra, 2000) , and treatment of HepG2 cells with the adenylate cyclase activator forskolin, the cyclic nucleotide phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), and/or stable cAMP analogues effectively stimulated the biogenesis of canalicular domains (Zegers and Hoekstra, 1997; Hoekstra, 1999, 2000) . Because the PKA displacing peptide shows specificity for type II PKA (Alto et al., 2003) , possibly type I PKA activity is involved in cAMP-stimulated canalicular membrane biogenesis. Preliminary experiments in our laboratory using type I-and type II-specific modulators of PKA activity (Christensen et al., 2003) support this hypothesis (Wojtal and van IJzendoorn, unpublished results). The data imply that PKA stimulates the development of a functional apical surface in HepG2 cells by the use of multiple regulatory proteins rather than via a single mechanism.
The involvement of PKA-RII␣-anchoring proteins in the cAMP/PKA-stimulated trafficking of specific proteins to the apical surface is in agreement with previous studies in which it was shown that Ht31, another peptide that inhibits PKA-AKAP interaction, prevents the translocation of water channels from intracellular sites to the apical surface in renal collecting duct principal cells in response to cAMP-elevating signals (Klussmann et al., 1999) . In these cells, the responsible AKAP was identified as AKAP18␦ (Henn et al., 2004) . The responsible AKAP in the present study remains to be determined, but may include AKAP350 (Shanks et al., 2002) or BIG2 (Li et al., 2003) , both of which localize to the Golgi apparatus in HepG2 cells and show reduced interaction with PKA-RII␣ in HepG2/IS-5 cells. Future studies (e.g., by using inactive mutants or down-regulation of these AKAPs) are needed to investigate this.
In addition to the trafficking of MDR1, displacement of PKA-RII␣ has pronounced effects on the trafficking of newly synthesized sphingolipid analogues from the Golgi. Indeed, direct Golgi-to-apical surface-directed trafficking of C6-NBD-(glyco)sphingolipids was effectively inhibited and most of the GlcCer analogue was rerouted to the basolateral domain. From there, (glyco)sphingolipid analogues were free to be internalized and delivered to the apical surface by means of transcytosis. PKA-RII␣ anchoring thus appears to be required for direct, but not indirect transport of sphingolipid analogues to the canalicular plasma membrane domain. The expression of some ABC transporters is accompanied by up-regulation of (glyco)sphingolipids (Lavie et al., 1996; Dijkhuis et al., 2003; Klappe et al., 2004) , and a significant fraction of cellular MDR1 is recovered from glycosphingolipid-enriched membrane fractions . We therefore hypothesized that the exclusion of newly synthesized glycosphingolipids from the direct Golgito-apical surface transport route in HepG2/IS-5 cells may be responsible for the delay in Golgi-to-apical surface trafficking of MDR1. A requirement of endogenous glycosphingolipids for efficient MDR1 trafficking is supported by our observation that the inhibition of GlcCer synthesis delays Golgi-to-apical surface trafficking of MDR1, similar to that observed in HepG2/IS-5 cells. Interestingly, also the effects of PDMP appeared to be specific for MDR1, because no visible effects on the canalicular appearance of MRP2 were observed. This suggests that the mechanisms by which MDR1 and MRP2 are delivered to the apical surface differ. This is supported by preliminary data from our laboratory showing that MDR1 and MRP2 are segregated within the apical plasma membrane bilayer (Aleksandrowicz and van IJzendoorn, unpublished results).
In conclusion, our data implicate PKA-RII␣ anchoring as an important parameter for both protein and lipid trafficking. Displacement of PKA-RII␣ diverts newly synthesized (glyco)sphingolipid analogues from the direct Golgi-to-apical surface transport route into the indirect pathway and impairs the trafficking of MDR1 to canalicular surface domains. In addition, trafficking of MDR1 to canalicular surface domains requires ongoing synthesis of endogenous glucosylceramide. Together, we propose that impaired anchoring of PKA-RII␣ and subsequent exclusion of glycosphingolipids from the direct Golgi-to-apical surface pathway may underlie the delay in direct Golgi-to-apical surface trafficking of MDR1. PKA-AKAP interactions at the Golgi may thus coordinate (glycosphingo)lipid and protein trafficking, which is a poorly understood process.
